Table 2 MNV characteristics at the time of presentation prior to the identification of CPHF:
From: Central posterior hyaloid fibrosis: evolution and outcomes
Variable | Value |
|---|---|
No. of eyes (n) | 10 |
Mean visual acuity (logMAR), Snellen equivalent | 1.308 ± 0.559 (20/407) |
Type 2 MNV (n, %) | 10 (100) |
No. of eyes where the MNV was treated previously elsewhere (n, %) | 3 (30) |
No. of eyes where the MNV was untreated (n, %) | 7 (70) |
Subfoveal location of MNV (n, %) | 10 (100) |
Absent fluid (n, %) | 1 (10) |
Presence of sub RPE fluid (n, %) | 0 (0) |
Presence of SRF (n, %) | 6 (60) |
Presence of IRF (n, %) | 9 (90) |
Presence of SHRM (n, %) | 1 (10) |
Presence of hard exudates (n, %) | 1 (10) |
Presence of hemorrhage (n, %) | 1 (10) |
Absence of posterior hyaloid detachment at the fovea (n, %) | 10 (100) |
Presence of ERM at the fovea (n, %) | 1 (10) |
No. of eyes treated with intravitreal anti-VEGF injections (n, %) | 6 (60) |
No. of eyes treated with pro-re-nata regimen (n, %) | 4 (67) |
No. of eyes treated with proactive monthly injection regimen (n, %) | 2 (33) |
Mean ± SD time interval (months) for the identification of CPHF | 27.3 ± 36.56 |
Mean number of intravitreal anti-VEGF injections taken prior to the identification of CPHF | 2.4 ± 2.63 (0–9) |